CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
2.015
+0.015 (0.75%)
Apr 24, 2025, 4:00 PM EDT - Market closed
CASI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 28.54 | 33.88 | 43.11 | 30.17 | 15.14 | Upgrade
|
| Revenue Growth (YoY) | -15.77% | -21.41% | 42.89% | 99.25% | 266.52% | Upgrade
|
| Cost of Revenue | 17.39 | 13.83 | 15.83 | 12.56 | 9.51 | Upgrade
|
| Gross Profit | 11.15 | 20.05 | 27.28 | 17.61 | 5.63 | Upgrade
|
| Selling, General & Admin | 41.44 | 41.84 | 37.78 | 38.41 | 27.48 | Upgrade
|
| Research & Development | 8.92 | 9.86 | 16 | 14.42 | 11.47 | Upgrade
|
| Other Operating Expenses | -0 | -6.37 | - | - | - | Upgrade
|
| Operating Expenses | 50.36 | 45.33 | 53.77 | 52.83 | 38.95 | Upgrade
|
| Operating Income | -39.21 | -25.28 | -26.49 | -35.22 | -33.31 | Upgrade
|
| Interest Expense | -0.87 | -0.02 | -0.06 | - | -0 | Upgrade
|
| Interest & Investment Income | 0.54 | 0.63 | 0.19 | 0.32 | 0.87 | Upgrade
|
| Earnings From Equity Investments | -1.19 | -0.05 | -0.85 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.19 | 0.2 | 3.24 | 0.32 | -1.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.19 | 0.76 | 0.04 | 0.09 | 0.08 | Upgrade
|
| EBT Excluding Unusual Items | -40.74 | -23.75 | -23.93 | -34.49 | -33.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.7 | -2.59 | -3.57 | 4.8 | 4.32 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.48 | - | -2.06 | -0.07 | 1.15 | Upgrade
|
| Asset Writedown | -0.7 | - | -8.72 | - | -1.54 | Upgrade
|
| Other Unusual Items | - | - | - | 0.47 | - | Upgrade
|
| Pretax Income | -39.26 | -26.34 | -38.28 | -35.84 | -47.51 | Upgrade
|
| Income Tax Expense | - | -0.08 | 1.98 | - | - | Upgrade
|
| Earnings From Continuing Operations | -39.26 | -26.26 | -40.26 | -35.84 | -47.51 | Upgrade
|
| Minority Interest in Earnings | - | -0.68 | -0.76 | -0.81 | -0.78 | Upgrade
|
| Net Income | -39.26 | -26.94 | -41.01 | -36.65 | -48.29 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 0.02 | - | - | - | Upgrade
|
| Net Income to Common | -39.26 | -26.96 | -41.01 | -36.65 | -48.29 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 13 | 14 | 14 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 13 | 14 | 14 | 11 | Upgrade
|
| Shares Change (YoY) | 14.82% | -2.10% | 0.27% | 23.23% | 15.12% | Upgrade
|
| EPS (Basic) | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | Upgrade
|
| EPS (Diluted) | -2.56 | -2.02 | -3.01 | -2.69 | -4.37 | Upgrade
|
| Free Cash Flow | -29.45 | -20.17 | -26.7 | -35.79 | -27.39 | Upgrade
|
| Free Cash Flow Per Share | -1.92 | -1.51 | -1.96 | -2.63 | -2.48 | Upgrade
|
| Gross Margin | 39.06% | 59.19% | 63.28% | 58.38% | 37.20% | Upgrade
|
| Operating Margin | -137.41% | -74.62% | -61.45% | -116.74% | -220.02% | Upgrade
|
| Profit Margin | -137.57% | -79.58% | -95.14% | -121.50% | -318.92% | Upgrade
|
| Free Cash Flow Margin | -103.19% | -59.54% | -61.94% | -118.63% | -180.87% | Upgrade
|
| EBITDA | -36.88 | -21.54 | -24.07 | -33.4 | -31.35 | Upgrade
|
| EBITDA Margin | -129.24% | -63.58% | -55.84% | -110.72% | -207.08% | Upgrade
|
| D&A For EBITDA | 2.33 | 3.74 | 2.42 | 1.82 | 1.96 | Upgrade
|
| EBIT | -39.21 | -25.28 | -26.49 | -35.22 | -33.31 | Upgrade
|
| EBIT Margin | -137.41% | -74.62% | -61.45% | -116.74% | -220.02% | Upgrade
|
| Revenue as Reported | 28.54 | 33.88 | 43.11 | 30.17 | 15.14 | Upgrade
|
Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.